Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity

1 Jul 2020

Abstract excerpt

Cellular senescence is a natural tumor suppression mechanism defined by a stable proliferation arrest. In the context of cancer treatment, cancer cell therapy-induced senescence (TIS) is emerging as an omnipresent cell fate decision that can be pharmacologically targeted at the molecular level to enhance the beneficial aspects of senescence. In prostate cancer (PCa), TIS has been reported using multiple different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced biosensing and bioanalysis techniques
Share to PARP inhibition in cancer therapy
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32630281
DOI: 10.3390/cells9071593

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor SensitivityPMID 32630281Read ↗

Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cellsSemantic proximity Read ↗

Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescenceSemantic proximity Read ↗

Taking Advantage of the Senescence-Promoting Effect of Olaparib after X-ray and Proton Irradiation Using the Senolytic Drug, ABT-263Semantic proximity Read ↗

The identification of senescence-specific genes during the induction of senescence in prostate cancer cells.Semantic proximity Read ↗

Apoptosis-coupled senescence causes cancer cell senotherapySemantic proximity Read ↗

Novel senolytic and senescence-suppressing compounds overcome senescence-driven chemoresistance in NSCLCSemantic proximity Read ↗

A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesisSemantic proximity Read ↗

Olaparib-Induced Senescence Is Bypassed through G2–M Checkpoint Override in Olaparib-Resistant Prostate CancerSemantic proximity Read ↗

Therapy-Induced Senescence in CancerSemantic proximity Read ↗

Stimulation of cellular senescent processes, including secretory phenotypes and anti-oxidant responses, after androgen deprivation therapy in human prostate cancer.Semantic proximity Read ↗

Role of senescence induction in cancer treatmentSemantic proximity Read ↗

A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.